Antigenics, Inc., a biotechnology company, through its subsidiaries, engages in the development of technologies and products to treat cancers, infectious diseases, and autoimmune disorders, primarily based on immunological approaches. It offers Oncophage, a personalized therapeutic cancer vaccine candidate, which is in Phase 3 clinical trials for the treatment of renal cell carcinoma and for metastatic melanoma. The company also offers AG-858, which is in Phase 2 clinical trial for the treatment of chronic myelogenous leukemia; AG-707, a therapeutic vaccine program that is in Phase 1 clinical trial for the treatment of genital herpes; Aroplatin, a liposomal chemotherapeutic, which is in...